Tiziana Life Sciences announced that a Phase 2a clinical of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (SPMS) has been expanded to include additional trial sites at Yale, Johns Hopkins, Cornell, Thomas Jefferson University, SUNY Buffalo, and UMass.
The trial was initiated at the end of 2023 at Brigham and Women’s Hospital. According to Tiziana, all of the sites selected are in the Northeastern US to make it possible for all subjects to have PET scans at the same facility to minimize variability.
Tiziana CEO Ivor Elrifi commented, “We are honored to collaborate with these prestigious institutions as we further expand our clinical trial. This milestone demonstrates our dedication to advancing innovative treatments for patients living with SPMS and underscores the potential of our platform to address complex neurodegenerative diseases.”
Read the Tiziana Life Sciences press release.
